Journal Article

FZJ-2017-07881

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Development of novel radionuclides for medical applications

Spahn, I.FZJ* ; Qaim, S. M. (Corresponding author)FZJ*

2018
Wiley New York, NY [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/jlcr.3578

Abstract: Medical radionuclide production technology is well established. There is, however, a constant need for further development of radionuclides. The present efforts are mainly devoted to non-standard positron emitters (e.g. 64Cu, 86Y, 124I, 73Se) and novel therapeutic radionuclides emitting low-range β- particles (e. g. 67Cu, 186Re), conversion or Auger electrons (e.g. 117mSn, 77Br) and α-particles (e.g. 225Ac). A brief account of various aspects of development work (i.e. nuclear data, targetry, chemical processing, quality control) is given. For each radionuclide under consideration the status of technology for clinical scale production is discussed. The increasing need of intermediate-energy multiple-particle accelerating cyclotrons is pointed out.

---

Contributing Institute(s):

1. Nuklearchemie (INM-5)

Research Program(s):

1. 573 - Neuroimaging (POF3-573) (POF3-573)

Appears in the scientific report 2018

---

Database coverage:
; BIOSIS Previews ; Current Contents - Life Sciences ; Current Contents - Physical, Chemical and Earth Sciences ; IF < 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---